Global HIV Point of Care (POC) Tests Pipeline Landscape Report 2023: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies

News provided by

Mar 15, 2024, 22:30 ET

DUBLIN, March 15, 2024 /PRNewswire/ -- The "HIV Point of Care (POC) Tests Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive information about the HIV Point of care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

HIV Point of care (POC) Tests is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often 'handheld' or may be small portable analyzers.

Scope

Extensive coverage of the HIV Point of care (POC) Tests under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of HIV Point of care (POC) Tests and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of HIV Point of care (POC) Tests under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 HIV Point of care (POC) Tests Overview

3 Products under Development
3.1 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development
3.2 HIV Point of care (POC) Tests - Pipeline Products by Territory
3.3 HIV Point of care (POC) Tests - Pipeline Products by Regulatory Path
3.4 HIV Point of care (POC) Tests - Pipeline Products by Estimated Approval Date
3.5 HIV Point of care (POC) Tests - Ongoing Clinical Trials

4 HIV Point of care (POC) Tests - Pipeline Products under Development by Companies
4.1 HIV Point of care (POC) Tests Companies - Pipeline Products by Stage of Development
4.2 HIV Point of care (POC) Tests - Pipeline Products by Stage of Development

5 HIV Point of care (POC) Tests Companies and Product Overview

6 HIV Point of care (POC) Tests- Recent Developments
6.1 Oct 10, 2023: Trinity Biotech Welcomes the Decision of the High Court of Kenya to Strike Out the Applications to Prevent the Procurement of Trinscreen HIV by the Kenyan Ministry of Health
6.2 Sep 27, 2023: Update on MedMira's Regulatory Path in Canada and the USA
6.3 Jun 14, 2023: Atomo and Newfoundland Sign Agreement for HIV Testing in Europe
6.4 Mar 22, 2023: Trinity Biotech welcomes TrinScreen HIV's inclusion in the New Kenyan HIV Testing Algorithm
6.5 Feb 28, 2023: Significant purchase order for HIV self-tests for Europe

7 Appendix

A selection of companies mentioned in this report includes

Abbott Rapid Diagnostics GmbH
Aldatu Biosciences Inc
Altratech Ltd
Atomo Diagnostics Ltd
Baebies Inc
BBB Technologies Inc
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Binx Health Inc
Bio-AMD Inc
Biocartis Group NV
BioHelix Corp
Bluejay Diagnostics Inc
Calypte Biomedical Corporation
Centre International de Reference Chantal Biya
Cepheid Inc
ChipCare Corp
CrossLife Technologies Inc
Cue Inc
Daktari Diagnostics, Inc.
Diagnostics For All Inc
Diagnostics for the Real World (Europe) Ltd
Endeavor Sciences Inc
Epinex Diagnostics Inc
ERBA Molecular Ltd
Fluxergy LLC
GAIA Medical Institute LLC
genedrive plc
Group K Diagnostics
Guangzhou Wondfo Biotech Co Ltd
HA TECH Pty Ltd
HeatFlow Technologies Inc
Identifysensors LLC
Imperial College London
Integrated Diagnostics Inc (Inactive)
Intuitive Biosciences Inc
Jan Biotech Inc
Jinvator Bio Med GmbH
Johns Hopkins University
Lynntech Inc
Maxim Biomedical Inc
MedMira Inc
Micronics Inc
Molbio Diagnostics Pvt Ltd
MyMD Pharmaceuticals Inc
Nanobiosym Inc
Newmark Diagnostics LLC
Northwestern University
Osel Inc
Philmedi Co Ltd
Prenetics Ltd
QuantuMDx Group Ltd
Quidel Corp
Radisens Diagnostics Ltd
Rheonix Inc
Roche Diagnostics International Ltd
Sedia Biosciences Corp
Sensible Diagnostics Inc
Senzo Inc
TheoremDx Inc
Trinity Biotech Plc
University of Connecticut
University of Minnesota
UrSure Inc
Ustar Biotechnologies (Hangzhou) Ltd.
Virax Biolabs Group Ltd
Wave 80 Biosciences Inc
Yaathum Biotech Pvt Ltd

For more information about this report visit https://www.researchandmarkets.com/r/w2cr75

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets